Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.
Human papillomavirus (HPV) type 16 infects the epithelial layer of cervical mucosa and is causally associated with the generation of cervical cancer. Langerhans cells (LC) are the resident APCs at the site of infection and therefore are responsible for initiating an immune response against HPV16. On the contrary, LC exposed to HPV16 do not induce a specific T cell immune response, which leads to the immune evasion of HPV16. Demonstrating that TLR7 and TLR8 are expressed on human LC, we hypothesized that imidazoquinolines would activate LC exposed to HPV16, leading to the induction of an HPV16-specific cell-mediated immune response. Surprisingly, both phenotypic and functional hallmarks of activation are not observed when LC are exposed to HPV16 virus-like particles and treated with imiquimod (TLR7 agonist). However, we found that LC are activated by 3M-002 (TLR8 agonist) and resiquimod (TLR8/7 agonist). LC exposed to HPV16 virus-like particles and subsequently treated with 3M-002 or resiquimod highly up-regulate surface activation markers, secrete proinflammatory cytokines and chemokines, induce CCL21-directed migration, and initiate an HPV16-specific CD8(+) T cell response. These data strongly indicate that 3M-002 and resiquimod are promising therapeutics for treatment of HPV infections and HPV-induced cervical lesions.
Fahey
Laura M
LM
Department of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Raff
Adam B
AB
Da Silva
Diane M
DM
Kast
W Martin
WM
D000276:Adjuvants, Immunologic / Q000378:metabolism / Q000494:pharmacology; D000634:Aminoquinolines / Q000378:metabolism / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology; D002478:Cells, Cultured; D018984:Epitopes, T-Lymphocyte / Q000276:immunology* / Q000378:metabolism; D005260:Female; D052162:Human papillomavirus 16 / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007093:Imidazoles / Q000378:metabolism / Q000494:pharmacology; D000077271:Imiquimod; D007111:Immunity, Cellular / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000627:therapeutic use; D007801:Langerhans Cells / Q000276:immunology* / Q000378:metabolism / Q000821:virology*; D030361:Papillomavirus Infections / Q000188:drug therapy / Q000276:immunology; D011804:Quinolines / Q000378:metabolism / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D051199:Toll-Like Receptor 7 / Q000819:agonists* / Q000378:metabolism; D051200:Toll-Like Receptor 8 / Q000819:agonists* / Q000378:metabolism; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000276:immunology
C526117:3M 002; D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000970:Antineoplastic Agents; D018984:Epitopes, T-Lymphocyte; D007093:Imidazoles; D007166:Immunosuppressive Agents; D011804:Quinolines; C495348:TLR7 protein, human; C495349:TLR8 protein, human; D051199:Toll-Like Receptor 7; D051200:Toll-Like Receptor 8; D000077271:Imiquimod; C402365:resiquimod